首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1542933

全球給藥輸液系統市場 - 2024-2031

Global Drug Delivery Infusion System Market - 2024-2031

出版日期: 2024年08月26日 | 出版商:

DataM Intelligence | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

全球藥物輸送輸液系統市場將於 2023 年達到 128 億美元，預計到 2031 年將達到 217 億美元，2024-2031 年預測期間複合年成長率為 6.8%。

藥物輸送輸注系統是一種醫療設備，旨在以受控和調節的方式將液體、藥物和治療劑直接注射到患者的血液中。這些系統廣泛應用於各種醫療保健環境，包括醫院、診所、門診護理機構和家庭醫療保健。它們對於提供藥物和治療化療、疼痛管理、胰島素治療和抗生素治療等疾病至關重要。

輸液系統由幾個關鍵部件組成，包括藥物儲存庫、推進機構、流量控制器、管道和用於給藥的靜脈導管。精確控制藥物傳遞的能力對於有效治療至關重要，特別是對於需要持續藥物管理的患者。

市場動態：

司機

慢性病盛行率上升和技術進步

全球給藥輸液系統市場的需求由多種因素所驅動。推動市場成長的主要驅動力是癌症和糖尿病等慢性疾病的高盛行率，尤其是老年患者，以及不斷進步的技術進步。

根據國家衛生中心的數據，2022 年，癌症是全球第二大死因，2022 年新增病例約為 1,918,030 例。此外，根據世界衛生組織的數據，到 2030 年，新病例數預計將增加 70% 左右。

同樣，根據世界衛生組織 2022 年的資料，估計有 2,000 萬新癌症病例和 970 萬人死於該疾病。大約有 5350 萬人在被診斷出患有癌症五年後仍然活著。根據統計，大約五分之一的人會在一生中的某個階段罹患癌症，其中大約九分之一的男性和十二分之一的女性死於這種疾病。

此外，關鍵參與者的策略（例如夥伴關係和協作以及技術進步）將推動該市場的成長。例如，2023 年 11 月，KORU Medical Systems, Inc. 宣布與生物製藥製造商達成新的開發協議。此次合作將專注於創建專為皮下免疫球蛋白（SCIg）治療而設計的下一代輸注系統並獲得監管部門的批准。這項措施體現了 KORU Medical 透過創新輸液技術改善患者生活品質的承諾。

此外，2023 年 6 月，Eitan Medical 宣布推出 Eitan Insights，這是一款專為家庭和專業輸液量身定做的基於雲端的新型輸液管理系統。該公司的輸液系統 Sapphire 現在配備了新型通用即插即用蜂窩配件 Sapphire Connect 和 Avoset（與 AvosetGo 應用程式配合使用），旨在連接輸液治療資料並將其傳輸到 Eitan Insights。這種整合透過提供即時資料和改善整體患者護理來增強輸液治療的管理。

限制

產品召回、輸液系統成本高昂、缺乏熟練的專業人員、嚴格的監管要求、患者安全問題和輸液不當以及報銷挑戰等因素預計將阻礙市場。

細分市場分析

全球給藥輸液系統市場根據產品類型、應用、最終用戶和地區進行細分。

容量輸液幫浦領域約佔全球給藥輸液系統市佔率的48.2%

預計容量輸液幫浦領域將在預測期內佔據最大的市場佔有率。容積輸液幫浦 (VIP) 是一種複雜的醫療設備，旨在以各種流速（從非常慢到非常快）精確、連續地輸送液體。

這些幫浦廣泛用於醫療保健環境中，以精確控制向患者注射靜脈 (IV) 藥物、液體、全血和血液製品。 VIP 讓醫療保健專業人員能夠準確管理關鍵物質進入患者體內的流量，確保最佳治療效果並最大限度地降低併發症的風險。

此外，行業產品發布和批准的主要參與者將推動該細分市場的市場成長。例如，2024 年 4 月，Baxter International Inc. 宣布其配備 Dose IQ 安全軟體的 Novum IQ 大容量輸液幫浦 (LVP) 已獲得美國食品藥物管理局 (FDA) 的 510(k) 批准。

Novum IQ 輸液平台增加了 LVP 模式，該平台已包括帶有 Dose IQ 安全軟體的百特注射器輸液幫浦 (SYR) 和 IQ 企業連接套件，使臨床醫生能夠在各種患者護理環境中操作統一的系統。 Novum IQ LVP 在美國的推出突顯了百特致力於輸液治療領域持續創新的決心。

同樣，2022 年 3 月，Fresenius Kabi 宣布其無線 Agilia Connect 輸液系統已獲得美國食品藥物管理局 (FDA) 的 510(k) 監管許可。該系統包括 Agilia 容量泵和 Agilia 注射泵，兩者都配備了採用 Vigilant Master Med 技術的 Vigilant 軟體套件。

此外，關鍵參與者的策略（例如夥伴關係和協作以及併購）將推動該市場的成長。例如，2022 年 3 月，Ivenix, Inc. 宣布已簽署最終協議，將被費森尤斯·卡比 (Fresenius Kabi) 收購。此次收購將把 Ivenix 的先進輸液系統與 Fresenius Kabi 的靜脈輸液和輸液治療產品相結合，為美國醫院創建全面的輸液產品組合。該交易的收購價格包括 2.4 億美元的預付款，以及與實現特定商業和營運目標相關的額外里程碑付款。

市場地域佔有率

北美約佔全球給藥輸液系統市佔率的43.6%

由於糖尿病、癌症和心血管疾病等慢性疾病的盛行率不斷上升，北美地區預計將在預測期內佔據最大的市場佔有率，這是推動給藥輸液系統市場的關鍵因素。這些疾病通常需要長期治療和準確的給藥，導致對輸注系統的需求增加，特別是胰島素幫浦和化療輸送設備。

輸液技術的進步，特別是配備改進的安全功能和連接性的智慧輸液幫浦的創建，正在推動市場的成長。這些創新提高了病患安全和治療效果，使輸液系統對醫療保健提供者越來越有吸引力。對北美醫療基礎設施的投資增加使得尖端輸液系統廣泛採用

此外，大量關鍵參與者的存在、先進的醫療基礎設施、產品發布和批准將推動該地區的市場成長。例如，2024 年 5 月，穆格公司的 CURLIN 8000 流動輸液系統獲得了美國食品藥物管理局 (FDA) 的 510(k) 許可，該系統專為家庭輸液環境而設計。這種先進的輸液平台是一種新型多療法系統，專為滿足家庭護理的獨特需求而量身定做。

此外，2023 年 8 月，ICU Medical 宣布美國食品藥物管理局 (FDA) 已為其 Plum Duo 輸液幫浦和 LifeShield 輸液安全軟體授予 510(k) 許可。這個新系統將於 2024 年初向美國客戶提供，它建立在 ICU Medical 屢獲殊榮的 Plum 360 輸液泵的精確輸送能力的基礎上。

同樣，2023 年 7 月，BD 宣布其更新的 BD Alaris 輸液系統已獲得美國食品藥物管理局 (FDA) 的 510(k) 批准。此次批准不僅可以修復現有系統，還可以使被認為是美國最全面的輸液系統恢復全面商業運作。

A drug delivery infusion system is a medical device designed to administer fluids, medications, and therapeutic agents directly into a patient's bloodstream in a controlled and regulated manner. These systems are widely used across various healthcare environments, including hospitals, clinics, ambulatory care settings, and home healthcare. They are essential for delivering pharmaceuticals and treatments for conditions such as chemotherapy, pain management, insulin therapy, and antibiotic administration.

Infusion systems consist of several key components, including a drug reservoir, a mechanism for propulsion, flow controllers, tubing, and an intravenous catheter for administration. The ability to precisely control the delivery of medications is crucial for effective treatment, particularly for patients who require ongoing medication management.

Market Dynamics: Drivers

Rising prevalence of chronic diseases & technological advancements

The demand for the global drug delivery infusion system market is driven by multiple factors. The major drivers fueling the growth of the market are the high prevalence of cancer and chronic diseases such as diabetes, especially in geriatric patients, and increasing technical advancements.

According to the National Centre for Health, in 2022, cancer was the second leading cause of mortality worldwide, with around 1,918,030 new cases registered in 2022. Cancer was responsible for 609,360 deaths all over the world. Moreover, as per WHO the number of new cases is expected to rise by around 70% by 2030.

Similarly, as per WHO data in 2022, it was estimated that there were 20 million new cancer cases and 9.7 million deaths attributed to the disease. Approximately 53.5 million individuals were alive five years after being diagnosed with cancer. Statistically, about 1 in 5 people will develop cancer at some point in their lives, with roughly 1 in 9 men and 1 in 12 women succumbing to the illness.

Moreover, key player's strategies such as partnerships & collaborations, and technological advancements would drive this market growth. For instance, in November 2023, KORU Medical Systems, Inc. announced a new development agreement with a biopharmaceutical manufacturer. This partnership will focus on creating and obtaining regulatory approval for a next-generation infusion system specifically designed for subcutaneous immunoglobulin (SCIg) therapy. This initiative reflects KORU Medical's commitment to improving patient quality of life through innovative infusion technologies.

Also, in June 2023, Eitan Medical announced the launch of Eitan Insights, a new cloud-based infusion management system tailored for home and specialty infusions. The company's infusion systems, Sapphire now equipped with the new universal plug-and-play cellular accessory Sapphire Connect and Avoset, which works with the AvosetGo app, are designed to connect and transmit infusion treatment data to Eitan Insights. This integration enhances the management of infusion therapies by providing real-time data and improving overall patient care.

Restraints

Factors such as product recalls, the high cost of infusion systems, lack of skilled professionals, stringent regulatory requirements, patient safety concerns & improper infusion, and reimbursement challenges are expected to hamper the market.

Market Segment Analysis

The global drug delivery infusion system market is segmented based on product type, application, end-user, and region.

The volumetric infusion pumps segment accounted for approximately 48.2% of the global drug delivery infusion system market share

The volumetric infusion pumps segment is expected to hold the largest market share over the forecast period. Volumetric infusion pumps (VIPs) are sophisticated medical devices designed to deliver precise and continuous amounts of fluids at a wide range of flow rates, from very slow to very fast.

These pumps are widely used in healthcare settings to precisely control the administration of intravenous (IV) medications, fluids, whole blood, and blood products to patients. VIPs enable healthcare professionals to accurately manage the flow of critical substances into a patient's body, ensuring optimal therapeutic effects and minimizing the risk of complications.

Moreover, key players in the industry product launches and approvals that would propel this segment's growth in the market. For instance, in April 2024, Baxter International Inc. announced that its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

This addition of the LVP modality to the Novum IQ Infusion Platform, which already includes Baxter's syringe infusion pump (SYR) with Dose IQ Safety Software and the IQ Enterprise Connectivity Suite, allows clinicians to operate a unified system across various patient care environments. The introduction of the Novum IQ LVP in the U.S. underscores Baxter's dedication to ongoing innovation in the field of infusion therapy.

Similarly, in March 2022, Fresenius Kabi announced that it had received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for its wireless Agilia Connect Infusion System. This system includes the Agilia Volumetric Pump and the Agilia Syringe Pump, both equipped with the Vigilant Software Suite featuring Vigilant Master Med technology.

In addition, key player's strategies such as partnerships & collaborations and mergers & acquisitions would drive this market growth. For instance, in March 2022, Ivenix, Inc. announced that it had entered into a definitive agreement to be acquired by Fresenius Kabi. The acquisition will combine Ivenix's advanced infusion system with Fresenius Kabi's intravenous fluids and infusion therapy offerings, creating a comprehensive portfolio of infusion products for U.S. hospitals. The deal involves a purchase price that includes an upfront payment of $240 million, along with additional milestone payments tied to the achievement of specific commercial and operational targets.

Market Geographical Share

North America accounted for approximately 43.6% of the global drug delivery infusion system market share

North America region is expected to hold the largest market share over the forecast period owing to the growing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions is a key factor driving the drug delivery infusion system market. These illnesses typically necessitate long-term treatment and accurate drug administration, leading to an increased demand for infusion systems, especially insulin pumps and chemotherapy delivery devices.

Advancements in infusion technology, particularly the creation of smart infusion pumps equipped with improved safety features and connectivity, are driving growth in the market. These innovations enhance patient safety and treatment effectiveness, making infusion systems increasingly attractive to healthcare providers. Increased investments in North America's healthcare infrastructure are enabling the widespread adoption of cutting-edge infusion systems

Moreover, a major number of key player's presence, well-advanced healthcare infrastructure, product launches, and approvals would drive this market growth in this region. For instance, in May 2024, Moog Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its CURLIN 8000 Ambulatory Infusion System, designed specifically for home infusion settings. This advanced infusion platform is a new multi-therapy system tailored to meet the unique demands of home care.

Also, in August 2023, ICU Medical announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Plum Duo infusion pump and LifeShield infusion safety software. This new system, which will be available to U.S. customers in early 2024, builds upon the precise delivery capabilities of ICU Medical's award-winning Plum 360 infusion pump.

Similarly, in July 2023, BD announced that its updated BD Alaris Infusion System had received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This approval allows for both the remediation of existing systems and a return to full commercial operations for what is considered the most comprehensive infusion system available in the United States.

Market Segmentation

By Product Type

Volumetric Infusion Pumps
Syringe Infusion Systems
Ambulatory Infusion Systems
Implantable Infusion Systems
Insulin Infusion Pumps
Enteral Infusion Systems
Large Volume Infusion Systems
Patient Controlled Analgesia (PCA)
Elastomeric Infusion Pumps

By Application

Oncology/Chemotherapy
Diabetes
Analgesia
Nutrition
Hematology
Pediatrics
Others

By End-User

Hospitals
Specialty Clinics
Ambulatory Surgery Centers
Homecare Settings

By Region

North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
South America
- Brazil
- Argentina
- The rest of South America
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Middle East and Africa

Market Competitive Landscape

The major global players in the drug delivery infusion system market include Medtronic, Eitan Medical, B. Braun SE, BD, Baxter, Terumo Corporation, Insulet Corporation., Fresenius Kabi AG, Arcomed, and ICU Medical, Inc. among others.

Key Developments

In January 2024, AbbVie introduced PRODUODOPA (foslevodopa/foscarbidopa) in the European Union, marking it as the first and only subcutaneous infusion therapy that provides continuous 24-hour delivery of levodopa for individuals with advanced Parkinson's disease.
In December 2023, TriSalus Life Sciences Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System (HCPCS) code for procedures involving the company's TriNav infusion system.
In June 2023, B. Braun launched its latest infusion management software, DoseTrac Enterprise, which provides organizations with a combination of real-time monitoring and historical reporting capabilities to gain deeper insights into their infusion pump fleet and related data. This new software platform enables healthcare providers to better comprehend and optimize their infusion pump infrastructure by offering a blend of live data visualizations and in-depth retrospective analytics.
In April 2023, Eitan Medical announced the launch of its innovative Avoset-connected infusion system, a multi-therapy ambulatory infusion pump designed to revolutionize post-acute care and specialty infusion therapy. This advanced system features compact and user-friendly technology that allows for remote monitoring of infusion treatment data, enhancing patient safety and improving the overall user experience.
In February 2023, Mindray introduced its BeneFusion i Series and u Series infusion systems, designed to enhance medication safety across various clinical environments. These systems feature high precision, adaptive customization, and user-friendly interfaces, ensuring reliable medication delivery.

Why Purchase the Report?

To visualize the global drug delivery infusion system market segmentation based on product type, application, end-user, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the drug delivery infusion system market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.

The global drug delivery infusion system market report would provide approximately 62 tables, 63 figures, and 183 pages.

Target Audience 2024

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Prevalence of Chronic Diseases & Technological Advancements
- 4.1.2. Restraints
  - 4.1.2.1. Product Recalls
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Volumetric Infusion Pumps
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Syringe Infusion Systems
6.4. Ambulatory Infusion Systems
6.5. Implantable Infusion Systems
6.6. Insulin Infusion Pumps
6.7. Enteral Infusion Systems
6.8. Large Volume Infusion Systems
6.9. Patient Controlled Analgesia (PCA)
6.10. Elastomeric Infusion Pumps

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Oncology/Chemotherapy *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Diabetes
7.4. Analgesia
7.5. Nutrition
7.6. Hematology
7.7. Pediatrics
7.8. Others

8. By End-User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Ambulatory Surgery Centers
8.5. Homecare Settings

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. The U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Medtronic*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Eitan Medical
11.3. B. Braun SE
11.4. BD
11.5. Baxter
11.6. Terumo Corporation
11.7. Insulet Corporation.
11.8. Fresenius Kabi AG
11.9. Arcomed
11.10. ICU Medical, Inc. (*LIST NOT EXHAUSTIVE)